JP2024513999A5 - - Google Patents
Info
- Publication number
- JP2024513999A5 JP2024513999A5 JP2023563063A JP2023563063A JP2024513999A5 JP 2024513999 A5 JP2024513999 A5 JP 2024513999A5 JP 2023563063 A JP2023563063 A JP 2023563063A JP 2023563063 A JP2023563063 A JP 2023563063A JP 2024513999 A5 JP2024513999 A5 JP 2024513999A5
- Authority
- JP
- Japan
- Prior art keywords
- mrna
- vaccine according
- respiratory viral
- antigenic polypeptide
- encoding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163175007P | 2021-04-14 | 2021-04-14 | |
| US63/175,007 | 2021-04-14 | ||
| US202163242346P | 2021-09-09 | 2021-09-09 | |
| US63/242,346 | 2021-09-09 | ||
| PCT/US2022/024669 WO2022221440A1 (en) | 2021-04-14 | 2022-04-13 | Influenza-coronavirus combination vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024513999A JP2024513999A (ja) | 2024-03-27 |
| JP2024513999A5 true JP2024513999A5 (https=) | 2025-04-21 |
Family
ID=81579694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023563063A Pending JP2024513999A (ja) | 2021-04-14 | 2022-04-13 | インフルエンザ－コロナウイルス組み合わせワクチン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240226277A1 (https=) |
| EP (1) | EP4322994A1 (https=) |
| JP (1) | JP2024513999A (https=) |
| AU (1) | AU2022258463A1 (https=) |
| WO (1) | WO2022221440A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL4023249T3 (pl) | 2014-04-23 | 2025-03-10 | Modernatx, Inc. | Szczepionki z kwasem nukleinowym |
| MA42543A (fr) | 2015-07-30 | 2018-06-06 | Modernatx Inc | Arn épitope peptidiques concatémériques |
| AU2016341309A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Cancer vaccines |
| EP4011451A1 (en) | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| WO2017201342A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding jagged1 for the treatment of alagille syndrome |
| CA3036831A1 (en) | 2016-09-14 | 2018-03-22 | Modernatx, Inc. | High purity rna compositions and methods for preparation thereof |
| MA46766A (fr) | 2016-11-11 | 2019-09-18 | Modernatx Inc | Vaccin antigrippal |
| WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
| US11905525B2 (en) | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| MA49914A (fr) | 2017-08-18 | 2021-04-21 | Modernatx Inc | Procédés analytiques par hplc |
| EP3675817A1 (en) | 2017-08-31 | 2020-07-08 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| EP3746090A4 (en) | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | RSV RNA Vaccines |
| WO2020061295A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| CA3113025A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| AU2020224103A1 (en) | 2019-02-20 | 2021-09-16 | Modernatx, Inc. | Rna polymerase variants for co-transcriptional capping |
| CN113874502A (zh) | 2019-03-11 | 2021-12-31 | 摩登纳特斯有限公司 | 补料分批体外转录方法 |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
| EP4274607A1 (en) | 2021-01-11 | 2023-11-15 | ModernaTX, Inc. | Seasonal rna influenza virus vaccines |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| WO2024086575A1 (en) * | 2022-10-17 | 2024-04-25 | BioNTech SE | Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection |
| KR20260021825A (ko) * | 2023-05-10 | 2026-02-13 | 세퀴러스 인코포레이티드 | 복합 백신 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2340499T3 (es) | 2001-06-05 | 2010-06-04 | Curevac Gmbh | Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado. |
| US9012219B2 (en) | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| JP2010531640A (ja) | 2007-06-29 | 2010-09-30 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション | 毒性化合物の分解方法 |
| CA2715078C (en) | 2007-09-26 | 2019-07-23 | Intrexon Corporation | Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression |
| SG10201408162PA (en) | 2007-12-11 | 2015-01-29 | Scripps Research Inst | Compositions and methods related to mrna translational enhancer elements |
| RU2013154295A (ru) | 2011-06-08 | 2015-07-20 | Шир Хьюман Дженетик Терапис, Инк. | КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК |
| EP2858679B2 (en) | 2012-06-08 | 2024-06-05 | Translate Bio, Inc. | Pulmonary delivery of mrna to non-lung target cells |
| EP3388834B1 (en) | 2013-03-15 | 2020-04-15 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| KR102354389B1 (ko) | 2013-08-21 | 2022-01-20 | 큐어백 아게 | Rna―암호화된 단백질의 발현을 증가시키는 방법 |
| WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
| CA2927254C (en) | 2013-12-30 | 2023-10-24 | Curevac Ag | Artificial nucleic acid molecules |
| CN111304231A (zh) | 2013-12-30 | 2020-06-19 | 库瑞瓦格股份公司 | 人工核酸分子 |
| EP4011451A1 (en) * | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| EP3405579A1 (en) | 2016-01-22 | 2018-11-28 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| AU2020224103A1 (en) | 2019-02-20 | 2021-09-16 | Modernatx, Inc. | Rna polymerase variants for co-transcriptional capping |
| JP2023527175A (ja) * | 2020-05-21 | 2023-06-27 | ヴァクセス・テクノロジーズ，インコーポレーテッド | ワクチン放出のための組成物およびデバイスならびにそれらの使用 |
| CA3170740A1 (en) * | 2020-05-29 | 2021-12-02 | Curevac Ag | Nucleic acid based combination vaccines |
| GB2596820A (en) * | 2020-07-07 | 2022-01-12 | Spicona Inc | Combination vaccine |
| CN112546211A (zh) * | 2020-10-23 | 2021-03-26 | 嘉晨西海(杭州)生物技术有限公司 | 基于mRNA的针对冠状病毒和流感病毒的联合疫苗及其制备方法 |
-
2022
- 2022-04-13 WO PCT/US2022/024669 patent/WO2022221440A1/en not_active Ceased
- 2022-04-13 US US18/555,130 patent/US20240226277A1/en active Pending
- 2022-04-13 JP JP2023563063A patent/JP2024513999A/ja active Pending
- 2022-04-13 AU AU2022258463A patent/AU2022258463A1/en active Pending
- 2022-04-13 EP EP22720863.4A patent/EP4322994A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024513999A5 (https=) | ||
| JP2024514182A5 (https=) | ||
| Serradell et al. | Efficient oral vaccination by bioengineering virus-like particles with protozoan surface proteins | |
| JP5331340B2 (ja) | インフルエンザウィルスワクチン組成物、及びその使用方法 | |
| TW202233232A (zh) | 遞送mRNA疫苗的脂質奈米顆粒 | |
| JP2024503698A5 (https=) | ||
| Wohlbold et al. | Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice | |
| CN1096851C (zh) | 疫苗组合物佐剂 | |
| Ernst et al. | Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines | |
| JP7817257B2 (ja) | ｍＲＮＡワクチンを送達するための脂質ナノ粒子 | |
| JP2011504486A5 (https=) | ||
| Ibañez et al. | M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A | |
| Gupta et al. | A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases | |
| JP2009539965A5 (https=) | ||
| JP2017035093A5 (https=) | ||
| Rynda-Apple et al. | Virus-like particles as antigenic nanomaterials for inducing protective immune responses in the lung | |
| Fotouhi et al. | Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus | |
| TW201427686A (zh) | 改良之疫苗組成物及使用方法 | |
| TW202333780A (zh) | 冠狀病毒疫苗 | |
| Lau et al. | The contribution of systemic and pulmonary immune effectors to vaccine-induced protection from H5N1 influenza virus infection | |
| JP2015500854A5 (https=) | ||
| JP2009514839A5 (https=) | ||
| JP2019500320A5 (https=) | ||
| Chaparian et al. | A virion-based combination vaccine protects against influenza and SARS-CoV-2 disease in mice | |
| JP2024015475A (ja) | コロナウイルスワクチン |